Loading clinical trials...
Loading clinical trials...
A Multi-Center, Single-Blind, Placebo-Controlled Phase 2 Study Assessing the Safety and Efficacy of Intravenous CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure
The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.
Age
18 - 85 years
Sex
ALL
Healthy Volunteers
No
Los Angeles, California, United States
Torrance, California, United States
Jacksonville, Florida, United States
Miami Beach, Florida, United States
Chicago, Illinois, United States
Iowa City, Iowa, United States
Detroit, Michigan, United States
Minneapolis, Minnesota, United States
The Bronx, New York, United States
Houston, Texas, United States
Start Date
June 1, 2009
Primary Completion Date
June 1, 2010
Completion Date
July 1, 2010
Last Updated
September 17, 2010
77
ACTUAL participants
CD-NP
DRUG
Lead Sponsor
Nile Therapeutics
NCT07372040
NCT06898515
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07199088